Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Arbutus Biopharma Corporation, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Roivant Sciences Ltd. September 10, 202570.6%
-
Arbutus Biopharma Corporation May 22, 202486.4%
-
Arbutus Biopharma Corporation May 24, 202376.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 16, 2026 | Roivant Sciences Ltd. | Grant or award | +5,054 | — | — |
| Jun 30, 2026 | Roivant Sciences Ltd. | Open-market sale | −12,380 | $35.28 | $436,766 |
| Jun 30, 2026 | Roivant Sciences Ltd. | Open-market sale | −200,000 | $35.45 | $7,090,000 |
| Jun 29, 2026 | Roivant Sciences Ltd. | Open-market sale | −200,000 | $34.44 | $6,888,000 |
| Jun 29, 2026 | Roivant Sciences Ltd. | Open-market sale | −600,000 | $34.59 | $20,754,000 |
| Jun 26, 2026 | Roivant Sciences Ltd. | Open-market sale | −300,783 | $33.92 | $10,202,559 |
| Jun 26, 2026 | Roivant Sciences Ltd. | Open-market sale | −325,000 | $34.07 | $11,072,750 |
| Feb 13, 2026 | Roivant Sciences Ltd. | Open-market sale | −150,784 | $26.49 | $3,994,268 |
| Feb 13, 2026 | Roivant Sciences Ltd. | Open-market sale | −225,000 | $26.50 | $5,962,500 |
| Feb 12, 2026 | Roivant Sciences Ltd. | Open-market sale | −150,000 | $26.72 | $4,008,000 |
| Feb 12, 2026 | Roivant Sciences Ltd. | Open-market sale | −275,000 | $26.76 | $7,359,000 |
| Feb 11, 2026 | Roivant Sciences Ltd. | Open-market sale | −425,000 | $26.67 | $11,334,750 |
| Dec 17, 2025 | Roivant Sciences Ltd. | Open-market sale | −432,718 | $23.05 | $9,974,150 |
| Dec 17, 2025 | Roivant Sciences Ltd. | Open-market sale | −155,076 | $23.02 | $3,569,850 |
| Dec 17, 2025 | Roivant Sciences Ltd. | Open-market sale | −189,538 | $23.17 | $4,391,595 |
Questions about Keith S. Manchester
What boards is Keith S. Manchester on?
Keith S. Manchester sits on the boards of Arbutus Biopharma Corporation and Roivant Sciences Ltd.
How long has Keith S. Manchester served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.